



Astec LifeSciences Ltd.

Date: 19th June, 2024

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08015

Dear Sir/Madam,

Sub.: Intimation under Regulations 30 and 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on approval received by Godrej Family from the Competition Commission of India for the family re-alignment

Further to the intimation given to the Stock Exchanges on 30th April, 2024 under Regulation 30 read with Regulation 30A in connection with the execution of the Family Settlement Agreement and a Brand & Non-Compete Agreement between the Members of Godrej Family, we have been informed by the Godrej Family members that the Competition Commission of India has approved the proposed re-alignment on 18th June, 2024.

The press release issued by the Competition Commission of India can be accessed on <https://cci.gov.in/combinatiion/press-release/details/403/0> and the press release issued by the Press Information Bureau can be accessed on <https://pib.gov.in/PressReleaselframePage.aspx?PRID=2026371>.

We request you to take the above on record.

Thanking you,

Yours sincerely,
For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236